These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

163 related items for PubMed ID: 34661906

  • 21. Aggressive invasive micropapillary salivary duct carcinoma of the parotid gland.
    Yamamoto H, Uryu H, Segawa Y, Tsuneyoshi M.
    Pathol Int; 2008 May; 58(5):322-6. PubMed ID: 18429833
    [Abstract] [Full Text] [Related]

  • 22. Novel therapeutic targets in salivary duct carcinoma uncovered by comprehensive molecular profiling.
    Gargano SM, Senarathne W, Feldman R, Florento E, Stafford P, Swensen J, Vranic S, Gatalica Z.
    Cancer Med; 2019 Dec; 8(17):7322-7329. PubMed ID: 31609094
    [Abstract] [Full Text] [Related]

  • 23. Clinical and immunohistologic typing of salivary duct carcinoma: a report of 50 cases.
    Jaehne M, Roeser K, Jaekel T, Schepers JD, Albert N, Löning T.
    Cancer; 2005 Jun 15; 103(12):2526-33. PubMed ID: 15900577
    [Abstract] [Full Text] [Related]

  • 24. Salivary Duct Carcinoma: An Update on Morphologic Mimics and Diagnostic Use of Androgen Receptor Immunohistochemistry.
    Udager AM, Chiosea SI.
    Head Neck Pathol; 2017 Sep 15; 11(3):288-294. PubMed ID: 28321773
    [Abstract] [Full Text] [Related]

  • 25. Prediction of clinical benefit from androgen deprivation therapy in salivary duct carcinoma patients.
    van Boxtel W, Verhaegh GW, van Engen-van Grunsven IA, van Strijp D, Kroeze LI, Ligtenberg MJ, van Zon HB, Hendriksen Y, Keizer D, van de Stolpe A, Schalken JA, van Herpen CM.
    Int J Cancer; 2020 Jun 01; 146(11):3196-3206. PubMed ID: 31745978
    [Abstract] [Full Text] [Related]

  • 26. Exceptional responses to pertuzumab, trastuzumab, and docetaxel in human epidermal growth factor receptor-2 high expressing salivary duct carcinomas.
    Park JC, Ma TM, Rooper L, Hembrough T, Foss RD, Schmitt NC, Sawhney R, Flanders A, Kang H.
    Head Neck; 2018 Dec 01; 40(12):E100-E106. PubMed ID: 30478962
    [Abstract] [Full Text] [Related]

  • 27.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 28. Increased expression of CD147 and MMP-9 is correlated with poor prognosis of salivary duct carcinoma.
    Piao S, Zhao S, Guo F, Xue J, Yao G, Wei Z, Huang Q, Sun Y, Zhang B.
    J Cancer Res Clin Oncol; 2012 Apr 01; 138(4):627-35. PubMed ID: 22215147
    [Abstract] [Full Text] [Related]

  • 29.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 30. [Survival analysis and immunohistochemical study of HER-2 and AR (androgen receptor) expression in salivary duct carcinoma].
    Otsuka K, Imanishi Y, Habu N, Sato Y, Shigetomi S, Fujii R, Sakamoto K, Tomita T, Fujii M, Kameyama K, Ogawa K.
    Nihon Jibiinkoka Gakkai Kaiho; 2013 Sep 01; 116(9):1024-32. PubMed ID: 24191589
    [Abstract] [Full Text] [Related]

  • 31. Characterization, treatment and outcomes of salivary ductal carcinoma using the National Cancer Database.
    Osborn V, Givi B, Lee A, Sheth N, Roden D, Schwartz D, Schreiber D.
    Oral Oncol; 2017 Aug 01; 71():41-46. PubMed ID: 28688689
    [Abstract] [Full Text] [Related]

  • 32. Clinical value of adjuvant therapy on the prognosis of ductal carcinoma of the major salivary gland: a large-scale cohort study.
    Zhang D, Li L, Wen T, Ma F.
    Eur Arch Otorhinolaryngol; 2023 Jan 01; 280(1):409-417. PubMed ID: 36036273
    [Abstract] [Full Text] [Related]

  • 33. The Clinical Utilisation and Duration of Treatment with HER2-Directed Therapies in HER2-Positive Recurrent or Metastatic Salivary Gland Cancers.
    Haigh JE, Patel K, Rack S, Jiménez-Labaig P, Betts G, Harrington KJ, Metcalf R.
    Curr Oncol; 2024 Sep 21; 31(9):5652-5661. PubMed ID: 39330047
    [Abstract] [Full Text] [Related]

  • 34. HER2/HER3-positive metastatic salivary duct carcinoma in the pleural effusion: A case report.
    Murata K, Kawahara A, Ono T, Takase Y, Abe H, Naito Y, Akiba J.
    Diagn Cytopathol; 2018 May 21; 46(5):429-433. PubMed ID: 29205961
    [Abstract] [Full Text] [Related]

  • 35. Invasive micropapillary salivary duct carcinoma: a distinct histologic variant with biologic significance.
    Nagao T, Gaffey TA, Visscher DW, Kay PA, Minato H, Serizawa H, Lewis JE.
    Am J Surg Pathol; 2004 Mar 21; 28(3):319-26. PubMed ID: 15104294
    [Abstract] [Full Text] [Related]

  • 36. The Benefits of Adjuvant Trastuzumab for HER-2-Positive Salivary Gland Cancers.
    Hanna GJ, Bae JE, Lorch JH, Haddad RI, Jo VY, Schoenfeld JD, Margalit DN, Tishler RB, Goguen LA, Annino DJ, Chau NG.
    Oncologist; 2020 Jul 21; 25(7):598-608. PubMed ID: 32310325
    [Abstract] [Full Text] [Related]

  • 37. [Clinicopathological analysis of 40 cases of salivary duct carcinoma].
    Lin N, Cai JH, Xu MJ, Kang P, Cheng ZF, He W.
    Zhonghua Kou Qiang Yi Xue Za Zhi; 2019 Jun 09; 54(6):416-419. PubMed ID: 31177683
    [Abstract] [Full Text] [Related]

  • 38. Salivary duct carcinoma with rhabdoid features: a salivary counterpart of pleomorphic lobular carcinoma of the breast.
    Kusafuka K, Kawasaki T, Maeda M, Yamanegi K, Baba S, Ito Y, Inagaki H, Nakajima T.
    Histopathology; 2017 Jan 09; 70(2):164-173. PubMed ID: 27079821
    [Abstract] [Full Text] [Related]

  • 39. Salivary Duct Carcinoma: An Aggressive Salivary Gland Carcinoma with Morphologic Variants, Newly Identified Molecular Characteristics, and Emerging Treatment Modalities.
    Rahman M, Griffith CC.
    Surg Pathol Clin; 2021 Mar 09; 14(1):111-126. PubMed ID: 33526216
    [Abstract] [Full Text] [Related]

  • 40. Successful treatment of pulmonary metastatic salivary ductal carcinoma with trastuzumab-based therapy.
    Prat A, Parera M, Reyes V, Peralta S, Cedrés S, Andreu J, Huguet P, del Campo JM.
    Head Neck; 2008 May 09; 30(5):680-3. PubMed ID: 17972317
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 9.